Creo Medical (CREO) AI Stock Analysis

• Market Cap: £59.29M
• Dividend Yield: N/A
• Average Volume (3M): 975.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 278
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.00
• Shares Outstanding: 412,473,330
• 10 Day Avg. Volume: 668,834
• 30 Day Avg. Volume: 975,484
• PEG Ratio: -0.17
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 17.63
• P/FCF Ratio: -3.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: 14.00p ▲(37.93% Upside)

The score is held back primarily by poor financial performance (sharp revenue decline, large losses, and continued cash burn). Technicals are a partial offset with strong trend and positive MACD, but very overbought RSI increases near-term risk. Valuation impact is neutral since P/E and dividend yield were not provided.

Positive Factors

Recurring consumables revenue

Creo's business model includes recurring consumable sales tied to each procedure. This creates a durable, predictable revenue stream once clinical adoption is established, improving lifetime customer value and smoothing unit-sales volatility over the medium term.

Operational restructuring and strategic stake sale

A 24% cost reduction plus the 51% CME stake sale to Micro‑Tech represents a structural change: lower fixed costs and strategic partnership can supply resources, distribution or capital. Combined with higher continuing-operation revenue, this materially improves operational resilience.

Improving leverage and equity coverage

Slightly reduced debt and equity covering a large portion of assets reduce solvency risk and provide a balance-sheet buffer. This improves financial flexibility long-term, lowering refinancing pressure and enabling more sustainable funding of R&D and commercialization.

Negative Factors

Severe revenue decline

A collapse in revenue indicates material loss of commercial traction or discontinued operations, shrinking scale and limiting the firm's ability to achieve operating leverage. This structural shrinkage raises the likelihood of further capital raises and constrains long‑term market positioning.

Persistent negative operating and free cash flow

Ongoing negative operating and free cash flows show the company is burning cash to fund operations. Over months this reduces runway, curtails investment in sales and R&D, increases refinancing risk, and may necessitate dilutive financing or asset sales to sustain operations.

Sustained net losses and margin deterioration

Large net losses and worsening margins indicate persistent unprofitability and cost structure issues. This undermines ability to self‑fund growth, erodes equity, and suggests structural challenges in pricing, unit economics or scale that must be addressed for long‑term viability.

Creo Medical Business Overview & Revenue Model

Company Description

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.

How the Company Makes Money

Creo Medical generates revenue primarily through the sale of its medical devices and related consumables. The company earns money by selling its CROMA system and the associated single-use devices required for its operation during surgical procedures. Additionally, Creo Medical benefits from recurring revenue generated through the sale of these consumables, which are needed for each procedure. Significant partnerships with hospitals and healthcare providers enhance its market reach and adoption of its technologies, contributing to a steady revenue stream. Moreover, the company may explore collaborations and licensing agreements to expand its product offerings and market presence, further bolstering its earnings potential.

Creo Medical Financial Statement Overview

Summary

Weak fundamentals: revenue fell sharply ($30.8M in 2023 to $4M in 2024), profitability is deeply negative (net income -$28.7M), and operating/free cash flow remain negative. Balance sheet shows slightly improved debt metrics, but equity and assets declined year-over-year.

Income Statement

Creo Medical has experienced a significant drop in total revenue from $30.8M in 2023 to $4M in 2024, resulting in a negative revenue growth rate. The gross profit margin decreased from 49.7% in 2023 to 47.5% in 2024. Net profit margin worsened due to substantial losses, with a net income of -$28.7M in 2024. The EBIT and EBITDA margins remain deeply negative, reflecting ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio improved slightly as total debt decreased. However, stockholders' equity also declined, indicating potential concerns in financial structuring. The equity ratio is relatively healthy, with equity covering a significant portion of total assets, but overall asset levels have decreased year-over-year.

Cash Flow

Operating cash flow remains negative, indicating ongoing cash burn from operations. Free cash flow is also negative, though it improved slightly from 2023 to 2024. The free cash flow to net income ratio is unfavorable, suggesting insufficient cash generation to cover operational losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.20M	4.00M	30.80M	27.17M	25.16M	9.43M
Gross Profit	1.00M	1.90M	15.30M	10.01M	9.02M	2.44M
EBITDA	-9.50M	-26.10M	-20.70M	-27.62M	-27.54M	-21.77M
Net Income	16.90M	-28.70M	-21.70M	-26.94M	-24.59M	-20.32M
Balance Sheet
Total Assets	68.80M	65.00M	76.60M	75.34M	100.61M	92.46M
Cash, Cash Equivalents and Short-Term Investments	20.50M	8.70M	18.50M	13.10M	43.53M	45.09M
Total Debt	4.20M	4.40M	8.30M	11.70M	10.56M	12.36M
Total Liabilities	7.90M	22.60M	16.80M	25.93M	27.29M	29.66M
Stockholders Equity	60.90M	42.40M	59.80M	49.40M	73.32M	62.81M
Cash Flow
Free Cash Flow	15.30M	-22.60M	-22.80M	-28.26M	-32.10M	-16.66M
Operating Cash Flow	15.30M	-22.20M	-21.60M	-24.99M	-25.98M	-16.09M
Investing Cash Flow	-3.30M	15.30M	-18.30M	-6.03M	-7.87M	-21.16M
Financing Cash Flow	-600.00K	16.20M	29.80M	400.00K	31.99M	1.33M

Creo Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CREO, the sentiment is Positive. The current price of 10.15 is below the 20-day moving average (MA) of 11.88, below the 50-day MA of 10.85, and below the 200-day MA of 11.97, indicating a bullish trend. The MACD of 0.92 indicates Negative momentum. The RSI at 75.77 is Negative, neither overbought nor oversold. The STOCH value of 84.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:CREO.

Creo Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	77 Outperform	£200.97M	30.17	20.31%	3.48%	10.80%	1.75%
SN	70 Outperform	£10.54B	28.60	9.30%	2.35%	2.51%	56.56%
AMS	69 Neutral	£466.31M	50.71	3.66%	1.25%	68.03%	-18.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CREO	48 Neutral	£59.29M	―	―	―	―	―
SUN	43 Neutral	£4.20M	-3.00	-15.46%	―	-4.98%	-114.29%

Creo Medical Corporate Events

Creo Medical Delivers 50% Revenue Growth and Narrows Losses on Strong FY25 Product Adoption

Creo Medical Group reported a strong FY25 performance, with revenue rising 50% to £6.0m and underlying operating costs reduced by 20% to £18.4m, narrowing its underlying operating loss by more than 40% to £13.3m and ending the year with £12.4m in cash. Growth was driven by continued clinical adoption and higher utilisation of its core products, including increased use of the Speedboat Notch device in advanced gastrointestinal procedures, encouraging early reception of its newly launched SpydrBlade Flex in the US, UK and EU, and progress in its MicroBlate ablation portfolio through commercial sales and limited market releases tied to clinical studies. Management signalled confidence in further sequential growth and improving operational efficiency in FY26, positioning the company on a path toward self-sustaining cash flows and reinforcing its standing in the growing market for minimally invasive endoscopic oncology treatments.

The most recent analyst rating on (GB:CREO) stock is a Hold with a £11.00 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.